Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
Status:
Active, not recruiting
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared
with placebo, on heart failure disease-specific biomarkers, symptoms, health status, and
quality of life in patients with chronic heart failure with reduced systolic function.